Enzyme Replacement Therapy Market to Reach $21.9 Billion by 2035

Enzyme replacement therapy market was valued at $12.0 billion in 2025 and is projected to reach $21.9 billion by 2035, growing at a CAGR of 6.20% during the forecast period (2026–2035). Market growth is driven by the rising prevalence of rare genetic disorders, particularly lysosomal storage diseases (LSDs), and increasing access to specialized treatments. According to the World Health Organization, rare diseases collectively affect over 300 million people globally, creating significant demand for targeted therapies such as enzyme replacement treatments. This growing patient pool, combined with advancements in biologics manufacturing and improved diagnosis rates, is accelerating the adoption of ERT across hospitals and specialty care centers.

Browse the full report description of “Enzyme Replacement Therapy Market Size, Share & Trends Analysis Report by Product Type (Imiglucerase / Velaglucerase, Agalsidase Alfa/Beta, Alglucosidase Alfa, Laronidase, Idursulfase, Elosulfase Alfa, Others), by Disease Type (Gaucher, Fabry, Pompe, MPS, Others), by Route of Administration (IV, Intrathecal), by End-User (Hospitals, Specialty Clinics, Homecare), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/enzyme-replacement-therapy-market

Innovation Leaders Transforming the Enzyme Replacement Therapy Market

The key players in the enzyme replacement therapy market include top companies such as Pfizer, Sanofi, Takeda Pharmaceutical Company, Chiesi Farmaceutici, and BioMarin Pharmaceutical, among others. The market is witnessing steady growth driven by increasing diagnosis of lysosomal storage disorders such as Gaucher, Fabry, and Pompe diseases. Hospitals and specialty clinics are expanding infusion capabilities to support long-term biologic therapies, while home care infusion services are gaining traction to improve patient convenience and reduce healthcare burden.

• In March 2026, Chiesi Farmaceutici and Protalix BioTherapeutics announced that the European Commission approved a new every-4-weeks dosing regimen for Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. The approval provides a reduced treatment burden for patients requiring lifelong therapy and strengthens the commercialization of next-generation ERT solutions in Europe.

• In October 2025, JCR Pharmaceuticals announced a licensing agreement with Menagen Pharmaceutical Industries to commercialize its agalsidase beta biosimilar enzyme replacement therapy for Fabry disease across nine Middle East and North Africa markets, expanding global access to ERT treatments.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
  • By Product Type
  • By Disease Type
  • By Route of Administration
  • By End User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Pfizer, Sanofi, Takeda Pharmaceutical Company, Chiesi Farmaceutici, and BioMarin Pharmaceutical, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Enzyme Replacement Therapy Market Report Segment

By Product Type

• Imiglucerase / Velaglucerase (Gaucher Disease)
• Agalsidase Alfa / Beta (Fabry Disease)
• Alglucosidase Alfa (Pompe Disease)
• Laronidase (MPS I)
• Idursulfase (MPS II)
• Elosulfase Alfa (MPS IV)
• Others

By Disease Type

• Gaucher Disease
• Fabry Disease
• Pompe Disease
• Mucopolysaccharidoses
• Others

By Route of Administration

• Intravenous (IV)
• Intrathecal

By End User

• Hospitals
• Specialty Clinics
• Homecare Settings

Global Enzyme Replacement Therapy Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/enzyme-replacement-therapy-market